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Background: Abdominal surgery carries significant morbidity and mortality, which is in turn associated with an
enormous use of healthcare resources. We describe the clinical course of 30 Intensive Care Unit (ICU) patients who
underwent abdominal surgery and showed severe infections caused by Klebsiella pneumoniae sequence type (ST)
258 producing K. pneumoniae carbapenemase (KPC-Kp). The aim was to evaluate risk factors for mortality and the
impact of a combination therapy of colistin plus recommended regimen or higher dosage of tigecycline.
Methods: A prospective assessment of severe monomicrobial KPC-Kp infections occurring after open abdominal
surgery carried out from August 2011 to August 2012 in the same hospital by different surgical teams is presented.
Clinical and surgical characteristics, microbiological and surveillance data, factors associated with mortality and
treatment regimens were analyzed. A combination regimen of colistin with tigecycline was used. A high dose of
tigecycline was administered according to intra-abdominal abscess severity and MICs for tigecycline.
Results: The mean age of the patients was 56.6 ± 15 and their APACHE score on admission averaged 22.72. Twenty
out of 30 patients came from the surgical emergency unit. Fifteen patients showed intra-abdominal abscess, eight
anastomotic leakage, four surgical site infection (SSI) and three peritonitis. The overall crude ICU mortality rate was
40% (12 out of 30 patients). Twelve of the 30 patients were started on a combination treatment of high-dose
tigecycline and intravenous colistin. A significantly lower mortality rate was observed among those patients
compared to patients treated with approved dose of tigecycline plus colistin. No adverse events were reported
with high doses of tigecycline.
Conclusions: Critically-ill surgical patients are prone to severe post-surgical infectious complications caused by
KPC-Kp. Timely microbiological diagnosis and optimizing antibiotic dosing regimens are essential to prevent worse
outcomes. Further studies and well-controlled clinical trials are needed to define the optimal treatment of
infections by KPC-Kp and, more generally, carbapenem-resistant bacteria.
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Abdominal surgery carries significant morbidity and
mortality, which is in turn associated with an enormous
use of healthcare resources. Sepsis is a serious complica-
tion and may be diagnosed during pre-, intra-, or post-
operative periods [1,2].
Klebsiella pneumoniae (Kp) is an emerging major
pathogen in surgical settings, especially after emergency
abdominal surgery [3,4].
In 2010, the first outbreak of K. pneumoniae
carbapenemase (KPC)-Kp sequence type (ST)258 was
reported in ICU patients in Palermo, Italy [5-7].
Since then, colonizations or infections with KPC-Kp
have become endemic and have also been described in dif-
ferent healthcare settings, such as in surgical wards [8].
The aim of this study was to describe the clinical as-
pects of surgical KPC-Kp infections in patients who had
undergone emergency or elective abdominal surgery.
Risk factors for mortality and the impact of a combin-
ation therapy of colistin plus recommended regimen or




This was a prospective case series study of post-surgical pa-
tients with monomicrobial bloodstream infections caused
by KPC-Kp, admitted to the Intensive Care Unit (ICU) of
the “Paolo Giaccone” University Hospital in Palermo, Italy.
The ICU under study is an 8-bed general ICU that
provides care to emergency and elective surgery recipi-
ents, with approximately 250 patients admitted to the
ICU annually.
In the period under study, the infection control policy
in the ICU did not include routine surveillance cultures
or screening of high-risk patients on admission. Special
attention was given to hand hygiene measures, with an
alcoholic hand rub solution placed in the proximity of
every ICU bed or provided as a personal pocket dispen-
ser. Furthermore, the ICU had a policy of infection con-
trol which included restricting the use of antibacterial
drugs and clinical practice guidelines for infections with
multidrug- resistant pathogens. A structured system for
the surveillance of antimicrobial resistance has been
implemented since June 2009.
A 3-monthly serial surveillance program for multidrug
resistant Gram negative bacilli, including active surveil-
lance cultures, has been carried out in the Surgical
Emergency Unit since January 2010. High-risk patients
are routinely screened on admission.
Patients
We enrolled all postoperative abdominal surgery pa-
tients admitted from August 1, 2011 to August 31, 2012,who remained in the ICU for at least 48 hours and had
at least two positive blood cultures for KPC-Kp. Organ
failure was the leading cause of admission (65%)
followed by monitoring/weaning from mechanical venti-
lation (35%).
All patients were treated with combined intravenous
colistin (colistimethate sodium, 1 mg of colistin equals
12,500 IU) at a dosage of 5 mg/kg/day divided in three
equal doses and tigecycline (recommended dosage regi-
men 100 mg initially, followed by 50 mg every 12 hours).
The antimicrobial regimen was maintained or adapted
according to the results of susceptibility testing. Patients
who developed a severe intra-abdominal abscess were
started on high-dose (initial dose of 200 mg then 100
q12) tigecycline combined with colistin. Because
tigecycline MICs between 0.8-1 μg/ml are close to the
upper limit of the European Committee on Antimicro-
bial Susceptibility Testing (EUCAST) susceptibility
range, they were considered suboptimal and taken into
account when making this decision (http://www.eucast.
org) [9].
The study protocol was approved by the Ethics
Committee of the Azienda Ospedaliero-Universitaria
Policlinico “P. Giaccone”, Palermo, Italy. Before
starting treatment, informed consent, also regarding
publication of the patient’s details, was obtained from
each patient’s next of kin in accordance with the
principles of the Declaration of Helsinki.
Data collection
General data, which included age, gender, infection site,
date of admission and discharge from the surgery ward
and ICU, chronic organ-function insufficiencies (as de-
fined by the APACHE II scale), underlying conditions
(i.e. alcoholism, smoking habit, diabetes mellitus, un-
cured malignancy and previous surgery), clinical outcome,
microbiological findings, superinfection, reinfection and
mortality were collected from ICU and surgical patient
charts. Illness severity was measured with APACHE II
scores based on the worst values in the first 24 h in the
ICU [10]. Organ failure and severity of Multiple-Organ
Dysfunction Syndrome (MODS) were evaluated using the
Sequential Organ Failure Assessment (SOFA) scale on ad-
mission and during the subsequent clinical course.
Episodes of Ventilator Associated Pneumonia (VAP) in
which KPC-Kp had been isolated were also included.
The diagnosis of VAP was based on clinical and micro-
biological criteria [11]. A clinical suspicion of VAP was
raised in patients with a Modified Clinical Pulmonary
Infection Score (CPIS) >6 [11,12].
Microbiological methods
Identification (ID) and antimicrobial susceptibility testing
(AST) were routinely performed using a microdilution
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Sparks, MD, US). Etest (bioMérieux) was used to deter-
mine susceptibility to colistin. Susceptibility and resistance
categories were assigned following EUCAST guidelines.
Phenotypic confirmation of the presence of carba-
penemases or overexpression of AmpC in combination
with porin loss was obtained using a commercial synergy
test (Rosco Diagnostica, Taastrup, Denmark). This test
was carried out on putative carbapenemase-producing
K. pneumoniae isolates based upon their screening
cut-off values for meropenem, according to the
recommended methods for detection of carba-
penemases in Enterobacteriaceae [5-7,10]. ST258 was
identified by Multi-locus Sequence Typing (MLST)
[www.pasteur.fr].
Statistical analysis
Frequency analysis was performed with chi-square test
or Fisher’s exact tests, as needed. Univariate analysis
of variance (ANOVA) was used for parametric vari-
ables. Risk ratios (RRs) and 95% confidence intervals
(CIs) were calculated for associations with demo-
graphic and clinical variables. The continuous vari-
ables found to be independent predictors of mortality
in the ICU were assessed using a linear regression
model, and slope coefficients with their standard error
were reported. Kaplan-Meier curve (log rank test) was
plotted to estimate the cumulative incidence of
mortality.
Results were expressed as mean ± standard deviation
(SD) or median [interquartile range (IR)] for continu-
ous variables or as percentages for categorical vari-
ables. Two-tailed tests were used and P values less
than 0.05 were considered to be statistically signifi-
cant. Data were analyzed using Epi Info software, version
3.2.2, (Centers for Disease Control and Prevention)
and SPSS software (version 14.0; SPSS Inc., Chicago,
IL, USA).
Results
During the study period, we collected 30 cases of infec-
tion caused by KPC-Kp.
Patient characteristics are shown in Table 1. The mean
age of the patients was 56.6 ± 15 years, and the APACHE
score on admission averaged 23.4 ±1.7. Twenty of the 30
patients came from the surgical emergency unit. Fifty
percent of these patients had been hospitalized in the
previous two years. Four patients had chronic obstruct-
ive pulmonary disease (COPD) as underlying medical
condition and two had diabetes mellitus. Smoking habit
was present in the anamnesis of 16 patients, obesity in
two, alcohol abuse in four and cocaine abuse in one
patient. Multiple underlying conditions were observed in
6 patients.The most common surgical indication was rectal can-
cer in seven patients, followed by colon cancer in six pa-
tients. Other indications were less represented (Table 1).
KPC-Kp post-surgical infections were as follows: intra-
abdominal abscess in 15 cases, anastomotic leakage in
eight, surgical site infection (SSI) in four and peritonitis
in three patients, respectively. Figure 1 shows KPC-Kp
infection in a patient with rectal cancer.
As shown in Table 1, KPC-Kp was isolated from all
surgical samples as well as from broncho-alveolar lavage
(BAL) in 50% of the patients who developed ventilator-
associated pneumonia (VAP) during their ICU stay.
Fifteen of the 30 patients under study who had a
history of previous hospitalizations proved to be colo-
nized by KPC-Kp strains on admission to the surgical
emergency unit. Four patients acquired KPC-Kp
colonization during their stay in the surgical unit.
Ten patients had also been exposed to carbapenems
before admission.
All the KPC-Kp strains were resistant to imipenem
(MIC ≥16 μg/ml), meropenem (MIC ≥32 μg/ml) and
ertapenem (MIC ≥8 μg/ml). They were also resistant to
amikacin (MIC ≥64 μg/ml), amoxicillin- clavulanic acid
(MIC ≥32 μg/ml), cefepime (MIC ≥8 μg/ml), cefotaxime
(MIC ≥8 μg/ml), ceftazidime (MIC ≥64 μg/ml), cipro-
floxacin (MIC ≥4 μg/ml), levofloxacin (MIC ≥8 μg/ml),
piperacillin-tazobactam (MIC ≥128 μg/ml), tobramycin
(MIC ≥16 μg/ml), gentamicin (MIC ≥8 μg/ml) and
trimethoprim-sulfamethoxazole (MIC ≥320 μg/ml).
Before starting combined antibiotic treatment, all the
strains isolated from blood samples were susceptible
to colistin (MIC ≤0.5 μg/ml) and tigecycline (MIC
≤0.5 μg/ml). After starting the treatment, five strains
of KPC-Kp showed tigecycline MICs of 0.8 – 1 μg/ml.
The average duration of treatment with a combination
of tigecycline and intravenous colistin was 18 ± 6.5 days.
Twelve patients were administered a combined treat-
ment for more than 21 days. Two surviving patients
were treated with prolonged courses of combined anti-
biotic treatment, with more than twenty-day intervals
between courses. Twelve patients received a combin-
ation treatment of high-dose tigecycline and intravenous
colistin. They included the five cases with KPC-Kp iso-
lates exhibiting tigecycline MICs >0.5 μg/ml.
Overall crude ICU mortality rate was 40% (12 out of
30 patients). Risk factors for mortality in the ICU were
assessed (Table 2). Using univariate analysis, a better
outcome was associated with the presence of a surgical
drainage, and a worse one with a higher APACHE II
score and VAP. Treatment with high doses of tigecycline
was associated with lower mortality (P = 0.005). Klapan-
Meier curve showed that patients treated with high
doses of tigecycline had a significant favorable outcome
(log-rank test, p = 0.0035) (Figure 2).
Table 1 Characteristics of 30 post-abdominal surgical ICU with infection by KPC-3 Klebsiella pneumoniae ST258 clone
Patients
(age yrs, gender)
Source of KPC-Kp positive isolate Surgical infection Underlying disease Treatment Outcome
01. 22, F BAL1, Intraoperative Sample SSI 2 Crush Syndrome T + C3 Survived
02. 66, M Intraoperative Sample Intra-abdominal Abscess Colon Cancer HDT + C4 Survived
03. 54, F Percutaneous Fluid Pancreatic Abscess Chronic Pancreatitis HDT + C Survived
04. 61, M Intraoperative Sample Intra-abdominal Abscess Crohn’s Disease HDT + C Survived
05. 68, M BAL, Intraoperative Sample Intra-abdominal Abscess Colon Cancer HDT + C Survived
06. 60, F Percutaneous Fluid Liver Abscess Liver Cancer HDT + C Survived
07. 61, F Intraoperative Sample Intra-abdominal Abscess Colon Cancer HDT + C Survived
08. 75, F Drainage Fluid Perianal Abscess Rectal Cancer HDT + C Survived
09. 55, F Intraoperative Sample Intra-abdominal Abscess Colon Cancer HDT + C Survived
10. 57, F Drainage Fluid Perineal Abscess Rectal Cancer HDT + C Survived
11. 53, M BAL, Intraoperative Sample Intra-abdominal Abscess Colon Cancer T + C Died
12. 67, F Intraoperative Sample Intra-abdominal Abscess Colon Cancer HDT + C Survived
13. 56, M Intraoperative Sample Intra-abdominal Abscess Crohn’s Disease HDT + C Survived
14. 45, M BAL, Intraoperative Sample Intra-abdominal Abscess Pancreatic Cancer HDT + C Died
15. 57, F Percutaneous Fluid Pancreatic Abscess Chronic Pancreatitis T + C Survived
16. 20, M Percutaneous Fluid Liver Abscess Liver Cancer T + C Survived
17. 45, M BAL, Wound Sample SSI Gastric By Pass T + C Died
18. 55, M BAL, Intraoperative Sample Peritonitis Peritonitis T + C Died
19. 56, F BAL, Abdominal Drain Anastomotic Leak Rectal Cancer T + C Survived
20. 65, F BAL, Abdominal Drain Anastomotic Leak Rectal Cancer T + C Died
21. 84, M BAL, Abdominal Drain Anastomotic Leak Rectal Cancer T + C Died
22. 29, M Abdominal Drain Anastomotic Leak Colorectal Cancer T + C Died
23. 59, M Intraoperative Sample Anastomotic Leak Crohn’s Disease T + C Survived
24. 61, M BAL, Abdominal Drain Anastomotic Leak Colorectal Cancer T + C Died
25. 76, M BAL, Intraoperative Sample Peritonitis Peritonitis T + C Died
26. 79, M BAL, Abdominal Drain Anastomotic Leak Rectal Cancer T + C Died
27. 52, F BAL, Wound Sample SSI Gastric By Pass T + C Died
28. 51, F BAL, Wound Sample SSI Thyroid Cancer T + C Died
29. 52, F Intraoperative Sample Peritonitis Peritonitis T + C Survived
30. 62, M BAL, Wound Sample Anastomotic Leak Rectal Cancer T + C Survived
1BAL: Bronchoalveolar Lavage; 2SSI: Surgical Site Infection; 3 T + C: Tigecycline plus Colistin; 4HDT + C: High Dose Tigecycline plus Colistin.
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The results of our study draw attention to two important
issues: the impact of KPC-Kp bloodstream infection in
ICU patients who have had abdominal surgery, and the
use of standard or high doses of tigecycline in combin-
ation with polymyxins to treat infection due to KPC-Kp
in patients with serious surgical complications, such as
intra-abdominal abscesses [1,2,7]. Moreover, our study
highlights additional postoperative infectious complica-
tions, such as colorectal anastomotic leakage, which can
be responsible for severe sepsis [13].
Some results appear to be relevant. Firstly, in all
patients, sources other than blood samples yieldedKPC-Kp strains and all clinical isolates proved to be-
long to the pandemic clone KPC-Kp ST258. This con-
firms our previous reports suggesting that this strain may
have a possible selective advantage over other MDR path-
ogens in the hospital setting [5,6]. Moreover, about 50% of
our surgical patients were colonized by KPC-Kp at admis-
sion and had a history of previous hospitalization. Ten
patients had also received carbapenem therapy in the past.
This is consistent with data from surveillance studies that
report patients colonized with MDRGN before hospital
admission [5,8] and with previous literature data describ-
ing the prolonged carriage of multidrug resistant bacterial
strains following hospital discharge [8,14,15].
Figure 1 Computed Tomography scan of pelvis showed rectal
abscess (arrowhead).
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intra-abdominal abscess due to KPC-Kp. As in our pre-
vious report [8], this observation is consistent with those
of other authors, such as Hirsch [16], who describe even
higher clinical success rates when using polymyxins in
combination.
In our study, we report on the use of high-dose
tigecycline in patients with intra-abdominal abscess, es-
pecially in those with a less favorable clinical course andTable 2 Univariate analysis of risk factors associated to morta
infection by KPC-3 Klebsiella pneumoniae ST258 clone
Variable Dead (n = 12) Survivo
Male gender 8 (66.7) 7 (38.9)
Age, years, mean (SD) 57.1 (17.7) 56.0 (13
LOS in ICU, days, median (IQR) 20 (18.5-22.5) 18.5 (13
LOS in surgery ward, median (IQR) 6.5 (3.5-8) 8 (5–10
Previous hospitalization 6 (50.0) 11 (61.1
Surgical drainage 2 (16.7) 12 (66.7
Underlying conditions
Smoking 5 (41.7) 11 (61.1
Solid tumor 6 (50.0) 12 (66.7
APACHE II score, mean (SD) 24.5 (0.67) 22.7 (1.
Infection type
Septicemia 3 (25.0) 11 (61.1
VAP 4 (33.3) 6 (33.3)
Septicemia + VAP 5 (41.7) 1 ( 5.6)
Intestinal carriage of KPC-Kp 6 (50.0) 11 (61.1
Tigecycline + colistin
High dosage 2 (16.7) 12 (66.7
Data are expressed as No. (%), unless otherwise defined;* logistic regression; ^ linea
Abbreviations: CI confidence interval, SD standard deviation, LOS length of stay, IQR
Acute Physiology and Chronic Health Evaluation, VAP ventilator associated pneumowith KPC-Kp isolates showing MICs of tigecycline near
the upper limit of the EUCAST susceptibility range
http://www.eucast.org). Since tigecycline is one of the
few antibiotics which is generally active against KPC-Kp
ST258 epidemic strain, optimal dosing is critical for
maximal therapeutic effectiveness. There is still some de-
bate over appropriate dosage and the most favorable phar-
macokinetic/pharmacodynamic profiles in some kinds of
infection, such as MDR K. pneumoniae /Acinetobacter
baumannii urosepsis/bacteremia [17,18]. Some prelimi-
nary experiences with loading doses of 200 mg and
400 mg, then decreased by 50% to achieve a maintenance
dose (100 mg or 200 mg every 24 hours respectively) seem
to guarantee serum concentrations (3 and 6 mg/L respec-
tively) and urine concentrations (0.6 and 1.2 mg/L respec-
tively) that are two and four times higher than those
attained with the usual doses [18].
Tigecycline has been approved for the treatment of
intra-abdominal and skin and soft tissue infections (and
for community-acquired pneumonia in the USA),
although a warning was recently issued by the FDA
(www.fda.gov) and the European Medicines Agency
(EMA, www.ema.europa.eu), after clinical trials indicated
a higher mortality rate in patients treated with tigecycline
compared to control groups. A recent meta-analysis has
confirmed increased mortality and has also indicated that,lity in post-abdominal surgical ICU patients with
No. (%) of patients
rs (n = 18) Risk ratio 95% CI P value
1.57 0.84-2.92 0.080*
.9) 0.001 −0.011-0.14 0.895^
–30) 0.005 −0.017-0.027 0.644^
) −0.051 −0.112-0.010 0.098^
) 0.636 0.13-3.03 0.570*
) 0.44 0.22-0.85 0.005*
) 0.73 0.39-1.35 0.160*
) 0.42 0.09-1.94 0.150*
8) 0.147 0.051-0.242 0.004^
)
8.33 1.03-67.1 0.030*
) 0.85 0.44-1.65 0.320*
) 0.44 0.22-0.85 0.005*
r regression.
interquartile range, COPD chronic obstructive pulmonary disease, APACHE
nia.
Figure 2 Kaplan-Meier survival curves show significantly lower
mortality among patients treated with a combination therapy
of high-dosage tigecycline plus colistin compared with those
treated with recommended dosage of tigecycline plus colistin
(log-rank test, p = 0.0035).
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of clinical failure, septic shock, superinfections and other
adverse events that can lead to therapy with the drug
being discontinued. [19]. Yahav et al. advise against using
tigecycline as monotherapy, especially in the treatment of
serious infections [19,20].
Prolonged plasma half-life (24–48 hours) and pharma-
codynamic index (AUC/MIC) suggest, however, that
higher doses of tigecycline should be used. Nevertheless,
the off-label use of tigecycline and higher doses should
be reserved for the treatment of multidrug resistant
Gram negative infections in patients with serious intra-
abdominal infections, such as abscesses.
As we recently reported, we observed KPC-Kp isolates,
which developed increasing tigecycline MICs after treat-
ment [21]. It is therefore important to carefully evaluate
the benefit of a higher dose of tigecycline or other treat-
ment options in this complex cohort of patients.
Thirdly, our mortality rate was 40%, which is higher
than reported by other studies [22]. Nonetheless, our pa-
tients were particularly complicated and showed at least
one additional site of KPC-Kp infection, such as severe
intra-abdominal infection. In 16 cases, a KPC-Kp VAP
was also present. Although numerous studies have
shown that VAP frequently complicates the ICU pa-
tient’s course, the issue of whether or not critically-ill pa-
tients are at an increased risk of death because of the
acquired pneumonia remains controversial [23]. In a
large study analysis, VAP-attributed mortality was higher
in surgical patients and patients with intermediate (but
not high) Simplified Acute Physiologic Score II values
on ICU admission [24]. In our study, mean APACHE IIscore was higher in non-survivors than in survivors. It is
postulated that both derangements in acute physiology
and severity of underlying diseases at the time of admis-
sion could be responsible for mortality, rather than the
underlying conditions. Despite improvements in our
knowledge of the physiopathology of severe infection
and the evolution of diagnostic methods, antibiotic ther-
apy, postoperative care and surgical techniques, a sub-
stantial number of patients develop severe intra-
abdominal infection and advanced stages of septic insult
requiring admission to the ICU. The success of treat-
ment of these conditions is multifactorial and the best
antibiotic protocol may not suffice, unless adequate con-
trol of the focus of infection is achieved.
Fourthly, in our study underlying conditions, such as
COPD, diabetes and lifestyle risk factors such as smok-
ing, were often present. This is in line with the analysis
of Huttenen [25], who reported a high prevalence of
obesity and smoking and their association with poor
prognosis in patients with bacteraemia.
Our study is not without limitations. It includes a
small number of patients with very complex and hetero-
geneous conditions, as well as the bias associated with
non-random enrollment, as the choice of treatment was
based on the patients’ medical conditions.
Additionally, our results are not supported by studies
comparing different protocols. Moreover, antibiotic ther-
apy pattern and quality of spread of multidrug resistant
pathogens in the ICU under study could not be general-
ized. A further limitation was that data on all patients
with KPC-Kp bacteraemia admitted to our university
hospital during the study period was not available.
Surveillance of healthcare associated infections has be-
come an integral part of infection control and quality
assurance of healthcare in many countries. Gastmeier
et al. reported that effective surveillance could reduce
the NI rate by about 20–30% on average [26]. Surveil-
lance programs provide data about the organisms caus-
ing specific infections and their antibacterial drug
resistance patterns. Moreover, such programs can guide
clinical practices and infection prevention and control
efforts in different geographic regions and clinical set-
tings [6,26,27].
At present, hand hygiene and contact precautions have
been improved, including dedicated patient-care equip-
ment, disposable gloves and aprons, and environmental
cleaning. The ICU has been thoroughly cleaned and
respiratory equipment disinfected. Because of insuffi-
cient bed capacity, isolation is not feasible, but colonized
or infected patients are spatially segregated. Compliance
with hand hygiene and environmental cleaning proce-
dures are monitored. Staff adherence is strongly pro-
moted by weekly meetings between healthcare workers
and the hospital infection control team.
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In summary, present-day surgical intensive care units
continue to evolve with the latest technological ad-
vances. The modern ICU team provides continuous daily
care to the critically-ill surgical patient in close cooper-
ation with the surgical team. A vital role of the intensive
care specialist is to establish and enforce protocols,
guidelines and patient care pathways that ensure contin-
ued quality performance improvement. Despite the evo-
lution of sophisticated adjuncts to healthcare and the
improvement of structured critical care systems, the sur-
gical critical care specialist continues to play a key role
in improving patient outcomes.
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